Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

Condition:   Non-valvular Atrial Fibrillation
Interventions:   Drug: Xarelto;   Other: Experimental: Personalized information intervention
Sponsor:   University Hospital, Montpellier
Recruiting - verified April 2015

Morbidity and Mortality in Patients With Hypertrophic Cardiomyopathy: a CALIBER Study

Condition:   Hypertrophic Cardiomyopathy
Intervention:   Other: No intervention
Sponsors:   University College, London;   Inherited Cardiac Diseases Unit, The Heart Hospital, London
Active, not recruiting - verified April 2015

Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application

Condition:   Atrial Fibrillation
Intervention:   Other: radio-frequency catheter ablation of atrial fibrillation
Sponsor:   Yonsei University
Not yet recruiting - verified April 2015

Bipolar Radiofrequency Ablation Plus Argon Beam Coagulator Ablation for Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Procedure: argon beam coagulator ablation;   Procedure: bipolar radiofrequency ablation;   Device: argon beam coagulator (American,Valleylab);   Device: bipolar radiofrequency (AtricuteTM)
Sponsor:   Xinqiao Hospital of Chongqing
Not yet recruiting - verified April 2015

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Not yet recruiting - verified April 2015

Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach

Conditions:   Atrial Fibrillation;   Persistent or Longstanding Persistent Atrial Fibrillation
Intervention:   Device: AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation
Sponsor:   AtriCure, Inc.
Recruiting - verified April 2015

Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry

Condition:   Non-valvular Atrial Fibrillation
Intervention:  
Sponsors:   Mount Sinai School of Medicine;   Bristol-Myers Squibb
Recruiting - verified April 2015

Validation of Ambulatory Sleep Test (WP200/U) Compared In-lab Sleep Testing in Cardiac Subjects

Condition:   Sleep Disorders
Intervention:  
Sponsor:   Itamar-Medical, Israel
Not yet recruiting - verified February 2015

ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)

Conditions:   Thrombotic Stroke;   Atrial Fibrillation and Flutter
Intervention:  
Sponsor:   Muğla Sıtkı Koçman University
Recruiting - verified April 2015

Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation

Conditions:   Atrial Fibrillation;   Obstructive Sleep Apnea;   Cardiac Arrhythmias
Interventions:   Device: Home Sleep Testing Device;   Device: Continuous positive airway pressure ventilation (CPAP)
Sponsor:   Beth Israel Deaconess Medical Center
Not yet recruiting - verified April 2015

Outcome After Coronary Artery Bypass Grafting

Conditions:   Coronary Artery Disease;   Myocardial Infarction;   Angina Pectoris
Intervention:   Procedure: Coronary artery bypass surgery
Sponsors:   University of Oulu;   Universita di Verona;   Ospedali Riuniti Trieste;   University of Catania;   University of Leicester;   Centre Hospitalier Universitaire de Besancon;   Karolinska Institutet;   San Camillo Hospital, Rome;   Rennes University Hospital;   S. Anna Hospital;   Paracelsus Medical University;   Second University of Naples;   University of Parma
Recruiting - verified April 2015

Enhanced Diagnostics for Early Detection of Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: ECG
Sponsor:   University Hospital, Basel, Switzerland
Recruiting - verified April 2015

Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke

Condition:   Ischemic Stroke
Intervention:   Device: Reveal LINQ Insertable Cardiac Monitor
Sponsor:   North Shore Long Island Jewish Health System
Recruiting - verified April 2015

An Assessment of Dual Site Left Ventricular Endocardial Pacing

Conditions:   Atrial Fibrillation;   Ventricular Tachycardia;   Heart Failure
Intervention:   Procedure: Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol
Sponsor:   Oxford University Hospitals NHS Trust
Recruiting - verified April 2015

Management of Atrial Fibrillation With Flecainide : the AFFLEC Study

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Hellenic Cardiovascular Research Society
Recruiting - verified April 2015

Early Post-marketing Study of Eliquis (Apixaban)

Condition:   Non-valvular Atrial Fibrillation (NVAF)
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified February 2015

Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa

Conditions:   Atrial Fibrillation;   Hemorrhage
Interventions:   Drug: Dabigatran 75 mg;   Drug: Dabigatran 150 mg
Sponsor:   Boehringer Ingelheim
Completed - verified April 2015

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified April 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: edoxaban;   Drug: Enoxaparin;   Drug: Warfarin
Sponsors:   Daiichi Sankyo Inc.;   Covance;   Quintiles
Recruiting - verified April 2015

Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study

Condition:   Atrial Fibrillation
Intervention:   Other: Cryoballoon ablation
Sponsors:   Harald Verheij;   Thorax Centrum Twente;   Academisch Ziekenhuis Maastricht
Enrolling by invitation - verified April 2015

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified April 2015

Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery

Condition:   Coronary Heart Disease
Interventions:   Dietary Supplement: Placebo;   Dietary Supplement: High-anthocyanin rich corn flour
Sponsor:   Neuromed IRCCS
Recruiting - verified April 2015

Multimodality Prediction of Success of Atrial Fibrillation Rhythm Control Strategy

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Maastricht University Medical Center
Recruiting - verified April 2015

Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)

Condition:   Persistent Atrial Fibrillation
Interventions:   Device: Convergent Procedure EPi-Sense-AF Guided Coagulation System;   Device: Endocardial Catheter Ablation
Sponsor:   nContact Surgical Inc.
Recruiting - verified April 2015

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients

Conditions:   Stroke,;   Embolism
Intervention:   Other: Rivaroxaban ( Xarelto, BAY59-7939)
Sponsor:   Bayer
Recruiting - verified April 2015

Trial of Electrical Versus Pharmacological Cardioversion for RAFF in the ED

Conditions:   Atrial Fibrillation;   Atrial Flutter
Intervention:   Device: drug-shock vs shock only
Sponsors:   Ottawa Hospital Research Institute;   The Ottawa Hospital
Recruiting - verified April 2015

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Condition:   Non-valvular Atrial Fibrillation
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified December 2014

Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation FIBRILLATION

Conditions:   Ventricular Tachycardia;   Atrial Fibrillation
Interventions:   Drug: Ethanol;   Procedure: Ablation
Sponsors:   The Methodist Hospital System;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2015

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified April 2015

Anticoagulant Utilization Pattern

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Device: nMARQ Navigation Catheters;   Device: NaviStar ThermoCool Catheters
Sponsor:   Biosense Webster, Inc.
Recruiting - verified April 2015

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified April 2015

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Condition:   Atrial Fibrillation
Intervention:   Other: Patients with Atrial Fibrillation
Sponsors:   Janssen Scientific Affairs, LLC;   Duke Clinical Research Institute
Recruiting - verified April 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Hybrid AF -- A Prospective Registry

Condition:   Atrial Fibrillation
Intervention:   Procedure: Standard of Care
Sponsors:   Dhanunjaya Lakkireddy, MD, FACC;   Estech
Withdrawn - verified April 2015

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Completed - verified April 2015

Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation

Conditions:   Atrial Fibrillation New Onset;   Hemorrhage;   Prolonged QTc Interval;   Ventricular Tachycardia;   Medical Care; Complications, Late Effect of Complications
Interventions:   Drug: Ranolazine;   Drug: Placebo
Sponsors:   North Shore Long Island Jewish Health System;   Gilead Sciences
Active, not recruiting - verified April 2015

Efficiency Study Evaluating the Use of the PVAC Catheter Technology for Performing Ablation in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Device: Radiofrequency Ablation Procedure;   Device: Radiofrequency Ablation Procedure
Sponsors:   Newmarket Electrophysiology Research Group Inc;   Medtronic
Recruiting - verified April 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2015

Current Clinical Practice in the Management of Atrial Fibrillation in Greece: the MANAGE-AF Study

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   Hellenic Cardiovascular Research Society;   Bayer
Completed - verified April 2015

Measurement of Left and Right Atria From CT Scans of Cardiac Rhythm Disorder Cases

Condition:   Atrial Fibrillation
Intervention:   Other: There is no intervention that is a part of this study.
Sponsors:   Kardium Inc.;   St. Paul's Hospital, Canada
Completed - verified April 2015

Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study

Conditions:   Obstructive Sleep Apnea;   Atrial Fibrillation
Intervention:   Device: Implantable Loop Recorder Insertion
Sponsors:   Queen's University;   Medtronic
Recruiting - verified April 2015

Magnesium Sulphate for Treatment of New Onset Atrial Fibrillation in Medical Intensive Care Unit Patient

Condition:   Atrial Fibrillation
Interventions:   Drug: Placebo;   Drug: Magnesium sulphate
Sponsor:   Mahidol University
Recruiting - verified April 2015

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

Conditions:   Atrial Fibrillation;   Heart Failure
Interventions:   Procedure: Radiofrequency ablation;   Other: Conventional treatment
Sponsor:   Biotronik SE & Co. KG
Recruiting - verified April 2015

Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension

Conditions:   Essential Hypertension;   Atrial Fibrillation
Intervention:   Drug: Perindopril
Sponsors:   Montreal Heart Institute;   Servier
Active, not recruiting - verified April 2015

Odiparcil For The Prevention Of Venous Thromboembolism

Conditions:   Fibrillation, Atrial;   Deep Vein Thrombosis;   Pulmonary Embolism;   Venous Thromboembolism
Interventions:   Drug: Odiparcil;   Drug: Warfarin;   Drug: Coumadin
Sponsor:   GlaxoSmithKline
Completed - verified April 2015

APART: Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias

Condition:   Tachyarrhythmia
Interventions:   Device: Activation of preventive and therapeutic algorithms for treatment of AF;   Device: AF Prevention and Therapy Algorithms On
Sponsors:   Medtronic Bakken Research Center;   Medtronic
Completed - verified April 2015

Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study

Condition:   Arrhythmia
Intervention:   Device: Autointrinsic Conduction Search Algorithm
Sponsor:   St. Jude Medical
Completed - verified April 2015

Get CardioSmart

You're Invited

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points